For all the attention on U.S.-China AI competition, new studies point to China's rapid rise in biotechnology, especially for ...

By Justin Leverenz, Chief Investment Officer, Developing Markets Equities China is unique among developing markets, not only ...

A dual-track approach has gained momentum for biotech companies as capital markets remain volatile and acquirers become more ...

It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, ...

With finite natural resources and a growing demand for food, the world must find ways to overcome this challenge. One ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

The companies Pathos AI, Taysha Gene Therapies, and Abeona Therapeutics bagged the biggest biotech funding rounds overall in ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Cresilon and Rumi Scientific's leases are part of larger uptick in biotech leasing at Industry City. Skanska takes project ...